Chelsie Derman

Evidence from 3 recent studies explores microbiome modulation, early allergen exposure, and immune tolerance as pathways for food allergy prevention.

FDA approvals, at-home neuromodulation, phase 3 psychedelic data, and rising AI therapy use impacted the psychiatry field in the first quarter of 2026.

FDA approvals, new HAE guidance, epinephrine access shifts, and phase 3 peanut patch data defined major allergy developments across Q1 2026.

Rapid psychedelic therapies, accelerated TMS protocols, AI-driven care debates, and semaglutide’s link to reduced suicidality shaped psychiatry headlines in March 2026.

March 2026 allergy news: FDA label updates, mastocytosis NDA, and promising data for peanut patch, remibrutinib, and CRSwNP biologics.

BrainsWay’s SWIFT protocol reduced treatment visits from ~36 to 6 while maintaining response and remission rates in a randomized multisite trial.

Investigational RNA interference therapy targeting prekallikrein enters accelerated regulatory pathway as phase 2 trial evaluates long-acting prophylaxis for HAE.

This month in review features 7 allergy headlines in February 2026: FDA's decision on Dupilumab for AFRS, late-breaking data presented at AAAAI, & more.

Pooled REMIX-1/-2 data show remibrutinib reduced CSU activity within 12 hours, with greater UAS improvements vs placebo through day 7.

FDA approves dupilumab for allergic fungal rhinosinusitis, supported by phase 3 LIBERTY-AFRS-AIMS data showing reduced symptoms and corticosteroid or surgery use.

FDA clears iloperidone metabolite, milsaperidone, for acute bipolar I disorder and schizophrenia, expanding treatment options.

A phase 2a randomized, placebo-controlled study shows –7.35 MADRS difference at 2 weeks with SPL026 compared with placebo. However, the study is not advancing.

Phase 3 COMP006 shows significant MADRS reduction at week 6, signaling potential benefit in treatment-resistant depression.

Updated international guidance reinforces early self-administered on-demand therapy and integrates newer kallikrein-targeted agents into routine HAE management.

In this Q&A, investigators Maria Byazrova and Rudolf Valenta discuss findings on plasmablast's role in seasonal IgE surge when it comes to birch allergy.

FDA grants Priority Review for Takeda’s oveporexton, an oral orexin agonist for narcolepsy type 1, showing near-normal symptom control in phase 3.

The 2024 global update for urticaria preserves the stepwise algorithm and clarifies evidence on biomarkers, provocation testing, pediatric care, and emerging therapies.

FDA approvals, priority review decisions, and new data on treatment response and mechanisms highlight a month of progress in MDD and ADHD.

FDA clears pediatric HAE oral therapy as intranasal epinephrine and heat-treated peanut/egg OIT studies point to safer allergy care.

FDA prioritizes centanafadine's review for ADHD treatment, offering a novel first-in-class NDSRI option for adults, adolescents, and children.

Interim phase 2 results show NS002 delivered faster absorption and greater early epinephrine exposure than EpiPen, with comparable safety and tolerability.

Upton discusses an open-label trial showing a 30 mg per nut very low-dose oral immunotherapy strategy increased multi-nut tolerance and remained safe in children.

A 12-week study found that combining CBT with quetiapine lowered suicide risk more than quetiapine alone in adults with depressive or bipolar disorders.

Reduced IgE binding and blunted basophil activation in response to Gal d 1 and Gal d 2 suggest that heat-treated egg proteins could improve the safety of OIT for egg-allergic patients.

Post-hoc analysis of the FLAME trial shows treatment discontinuation in COPD is associated with transient withdrawal effects and increased exacerbation risk.

A study found that bronchodilator responsiveness more accurately forecasts FEV₁ decline and COPD development than polygenic risk scores.

Analysis of > 9,000 FDA reports highlights previously unrecognized adverse events, including myocardial stunning, nerve damage, and real-world drug ineffectiveness.

Neurolief’s physician-directed therapy brings supervised, noninvasive brain stimulation into the home for adults with MDD who have not responded to ≥ 1 antidepressant.

Patients with idiopathic pulmonary fibrosis treated with the STAT3 inhibitor TTI-101 had greater reductions in lung fibrosis scores and IL-6 levels than placebo at 12 weeks.

Repeat monthly dosing of sustained-release lidocaine ST-01 met primary and secondary endpoints in phase 2 trial, delivering durable pain relief in men with chronic scrotal pain.